Effective adjuvant chemotherapy for high-risk, localised prostate cancer

Bookmark and Share
Published: 30 May 2015
Views: 4360
Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA

Prof Sandler talks to ecancertv at ASCO 2015 about a federally funded phase III study found that adding docetaxel chemotherapy to standard hormone and radiation therapy reduces the risk of death for men with high-risk, localised prostate cancer.

Read the news article and watch the press conference for more.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.